No Picture
News

Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Issues Update on Intellectual Property and Newly Acquired Patents

SAN DIEGO, Jan. 23, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands a… […]

No Picture
News

First-of-Its-Kind “U.S. Drug Testing 2020: Trends and Predictions” Report from Confirm BioSciences Highlights New Challenges for Employers, Need for Flexible Testing

New Drug Laws, Higher Rates of Legal Marijuana and CBD Use Underscore Importance of Staying Up to Date

SAN DIEGO, Jan. 22, 2020 /PRNewswire/ — Confirm BioSciences, a leading provider of comprehensive screening tools and solutions, today announced th… […]

No Picture
News

Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients

– Randomized, placebo-controlled 12-week study showed mean liver fat reduction of up to 55% with MET409- 93% of patients showed liver fat reduction of at least 30% from baseline

SAN DIEGO, Jan. 22, 2020 /PRNewswire/ — Metacrine, Inc., a clinical-sta… […]

No Picture
News

Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinical Indications

– Broadens Development of DB102 Beyond Oncology and PAH- Monetizes DB102 Prior to ENGINE Data Read-out

SAN DIEGO, Jan. 21, 2020 /PRNewswire/ — Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today anno… […]

No Picture
News

Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium

SAN DIEGO, Jan. 21, 2020 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, today announced that a… […]

No Picture
News

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results

Conference Call and Webcast Scheduled for Tuesday, February 4

SAN DIEGO, Jan. 20, 2020 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq… […]

No Picture
News

Iconic actor Alan Alda, Scripps Research join forces to bring science communication training to West Coast

The partnership between the Alda Communication Training Company® and Scripps Research will empower scientists and medical professionals to convey complex topics to the public with clear and vivid communication

LA JOLLA, Calif., Jan. 17, 2020 /PRNewsw… […]

No Picture
News

FDA Grants Fast Track Designation to Arena Pharmaceuticals’ APD418 for Development in Decompensated Heart Failure Patients

– APD418 currently in Phase 1 clinical investigation – data expected this year

SAN DIEGO, Jan. 16, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track des… […]

No Picture
News

Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions

— Exclusive license option grants Bloom rights to intellectual property for genetic manipulation and extensive strain library of Akkermansia bacteria —

SAN DIEGO, Jan. 15, 2020 /PRNewswire/ — Bloom Science, a biopharmaceutical company focused on … […]

No Picture
News

Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares

SAN DIEGO, Jan. 14, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 3,538,462 shares of its common stock at a public offering price of $97.50 per s… […]